|
1
|
Wang Y and Wang Y: Pharmacological study
and clinical application of total glucosides of peony in autoimmune
diseases. Zhe Jiang Zhong Yi Yao Da Xue Xue Bao. 2:240–241, 244.
2007.(In Chinese).
|
|
2
|
Zhang HF, Hou P and Xiao WG: Clinical
observation on effect of total glucosides of paeony in treating
patients with non-systemic involved Sjogren syndrome. Zhong Guo
Zhong Xi Yi Jie He Za Zhi. 27:596–598. 2007.(In Chinese).
|
|
3
|
Li X, Li X, Wang G, Qian L and Wang Z:
Effectiveness and safety of total glucosides of peony in the
treatment of patients with Sjogren syndrome. An Hui Yi Xue.
5:370–371. 2006.(In Chinese).
|
|
4
|
Wu GL, Pu XH, Yu GY and Li TY: Effects of
total glucosides of peony on AQP-5 and its mRNA expression in
submandibular glands of NOD mice with Sjogren's syndrome. Eur Rev
Med Pharmacol Sci. 19:173–178. 2015.PubMed/NCBI
|
|
5
|
Carsons SE: Issues related to clinical
trials of oral and biologic disease-modifying agents for Sjogren's
syndrome. Rheum Dis Clin North Am. 34:1011–1023. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nguyen CQ, Gao JH, Kim H, Saban DR,
Cornelius JG and Peck AB: IL-4-STAT6 signal transduction-dependent
induction of the clinical phase of Sjögren's syndrome-like disease
of the nonobese diabetic mouse. J Immunol. 179:382–390. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Munder M, Eichmann K and Modolell M:
Alternative metabolic states in murine macrophages reflected by the
nitric oxide synthase/arginase balance: Competitive regulation by
CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol.
160:5347–5354. 1998.PubMed/NCBI
|
|
8
|
Choi YJ, Saez B, Anders L, Hydbring P,
Stefano J, Bacon NA, Cook C, Kalaszczynska I, Signoretti S, Young
RA, Scadden DT, et al: D-cyclins repress apoptosis in hematopoietic
cells by controlling death receptor Fas and its ligand FasL. Dev
Cell. 30:255–267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Elmansy H, Kotb A, Hammam O, Abdelraouf H,
Salem H, Onsi M and Elleithy T: Prognostic impact of apoptosis
marker Fas (CD95) and its ligand (FasL) on bladder cancer in Egypt:
Study of the effect of schistosomiasis. Ecancermedicalscience.
6:2782012.PubMed/NCBI
|
|
10
|
Nakajima H and Oka T: Analysis of
biochemical and biological functions of Fas-ligand (FasL) and Fas
on activated T cells in allo-immune response. Transplant Proc.
29:1096–1100. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Riddell SR, Elliott M, Lewinsohn DA,
Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds
TC, Corey L and Greenberg PD: T cell mediated rejection of gene
modified HIV specific cytotoxic T lymphocytes in HIV infected
patients. Nat Med. 2:216–223. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu GL, Li TY, Lu WW, Yu GY and Fan YS:
Effect of nourishing Yin, strengthening Qi and activating blood
decoction on Fas/FasL in salivary glands of NOD mice with Sjogren's
syndrome and their mRNA expression. Zhong Guo Zhong Yao Za Zhi.
38:4148–4151. 2013.(In Chinese).
|
|
13
|
Tzioufas AG, Kapsogeorgou EK and
Moutsopoulo HM: Pathogenesis of Sjögren's syndrome: What we know
and what we should learn. J Autoimmun. 39:4–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin L, Lloyd RV, Nassar A, Lappinga PJ,
Sebo TJ, Swartz K, Seys AR, Erickson-Johnson MR, Roth CW, Evers BR,
et al: HMGA2 expression analysis in cytological and
paraffin-embedded tissue specimens of thyroid tumors by relative
quantitative RT-PCR. Diagn Mol Pathol. 20:71–80. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim SH, Lee MK, Lee KY, Sung SH, Kim J and
Kim YC: Chemical constituents isolated from Paeonia
lactiflora roots and their neuroprotective activity against
oxidative stress in vitro. J Enzyme Inhib Med Chem. 24:1138–1140.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou X, Ding J, Zhu M, Mou C, Wang H, Wang
Y, He J, Chen R, Gao X and Yang Z: The effects on TNF-α and sICAM-1
in the adjuvant arthritis rat model by the total glucosides of
peony. Xin Jiang Yi Ke Da Xue Xue Bao. 12:1677–1679. 2009.(In
Chinese).
|
|
17
|
Pijpe J, van Imhoff GW, Spijkervet FK,
Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG and
Bootsma H: Rituximab treatment in patients with primary Sjögren's
syndrome: An open-label phase II study. Arthritis Rheum.
52:2740–2750. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Novljan Plešivčnik M, Rotar Z, Ambrožič A,
Vidmar G and Tomšič M: Comparison of the performance of the
different classification criteria for primary Sjögren's syndrome: A
prospective cohort study. Clin Rheumatol. 33:1657–1664. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi H, Yu CQ, Xie LS, Wang ZJ, Zhang P and
Zheng LY: Activation of TLR9-dependent p38MAPK pathway in the
pathogenesis of primary Sjögren's syndrome in NOD/Ltj mouse. J Oral
Pathol Med. 43:785–791. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Asamoto H, Akazawa Y, Tashiro S, Oishi M,
Azuma T, Koide S, Sudo K, Yokota H and Tochino Y: Infiltration of
lymphocytes in various organs of the NOD (non-obese diabetic)
mouse. J Jpn Diabetes Soc. 27:775–781. 1984.
|
|
21
|
Wang D, Xue L, Yang Y, Hu J, Li G and Piao
X: Temporal gene expression analysis of Sjögren's syndrome in
C57BL/6.NOD-Aec1Aec2 mice based on microarray time-series data
using an improved empirical Bayes approach. Mol Biol Rep.
41:5953–5960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vale DL: Recognition and management of
Sjögren's syndrome: Strategies for the advanced practice nurse.
Nurs Clin North Am. 35:267–278. 2000.PubMed/NCBI
|
|
23
|
Ramos-Casals M, Garcia-Carrasco M, Cervera
R, Filella X, Trejo O, de la Red G, Gil V, Sánchez-Tapias JM, Font
J and Ingelmo M: Th1/Th2 cytokine imbalance in patients with
Sjögren syndrome secondary to hepatitis C virus infection. Semin
Arthritis Rheum. 32:56–63. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mitsias DI, Tzioufas AG, Veiopoulou C,
Zintzaras E, Tassios IK, Kogopoulou O, Moutsopoulos HM and
Thyphronitis G: The Th1/Th2 cytokine balance changes with the
progress of the immunopathological lesion of Sjogren's syndrome.
Clin Exp Immunol. 128:562–568. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kang EH, Lee YJ, Hyon JY, Yun PY and Song
YW: Salivary cytokine profiles in primary Sjögren's syndrome differ
from those in non-Sjögren sicca in terms of TNF-α levels and
Th-1/Th-2 ratios. Clin Exp Rheumatol. 29:970–976. 2011.PubMed/NCBI
|
|
26
|
Mariette X: Pathophysiology of Sjogren's
syndrome. Ann Med Interne (Paris). 154:157–168. 2003.(In French).
PubMed/NCBI
|
|
27
|
Nagarkatti N: Tumor-derived Fas ligand
induces toxicity in lymphoid organs and plays an important role in
successful chemotherapy. Cancer Immunol Immunother. 49:46–55. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mor G, Gutierrez LS, Eliza M, Kahyaoglu F
and Arici A: Fas-fas ligand system-induced apoptosis in human
placenta and gestational trophoblastic disease. Am J Reprod
Immunol. 40:89–94. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saegusa K, Ishimaru N, Yanagi K, Mishima
K, Arakaki R, Suda T, Saito I and Hayashi Y: Prevention and
induction of autoimmune exocrinopathy is dependent on pathogenic
autoantigen cleavage in murine Sjögren's syndrome. J Immunol.
169:1050–1057. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang X, Brunner T, Carter L, Dutton RW,
Rogers P, Bradley L, Sato T, Reed JC, Green D and Swain SL: Unequal
death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2,
effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med.
185:1837–1849. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yung R, Kaplan M, Ray D, Schneider K, Mo
RR, Johnson K and Richardson B: Autoreactive murine Th1 and Th2
cells kill syngeneic macrophages and induce autoantibodies. Lupus.
10:539–546. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou Q, Bai T and Wu H: Expression of
Th1/Th2 and Fas/FasL in the labial salivary gland of patients with
Sjögren's syndrome and its significance. Xu Zhou Yi Xue Yuan Xue
Bao. 28:28–30. 2008.(In Chinese).
|
